We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 inΒ Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in...
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- β Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a...
-Project NextGen Collaboration will Support Capricorβs StealthXβ’ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.74 | -12.3745819398 | 5.98 | 6.05 | 4.685 | 521670 | 5.07993475 | CS |
4 | -1.05 | -16.693163752 | 6.29 | 7.28 | 4.685 | 328657 | 5.91964839 | CS |
12 | 1.19 | 29.3827160494 | 4.05 | 7.28 | 3.56 | 305185 | 5.6117034 | CS |
26 | 2.5 | 91.2408759124 | 2.74 | 7.28 | 2.68 | 269231 | 4.80910081 | CS |
52 | 1.11 | 26.8765133172 | 4.13 | 8.2212 | 2.68 | 213955 | 4.73094998 | CS |
156 | 1.32 | 33.6734693878 | 3.92 | 8.2212 | 2.56 | 267157 | 4.5642464 | CS |
260 | 4.74 | 948 | 0.5 | 12.32 | 0.2526 | 761448 | 5.8831975 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions